As of 2023, six therapeutic drugs manufactured in the iCELLis™ bioreactor were approved, and that number is expected to rise. Gain an overview of how scientists have used the iCELLis™ bioreactor family in a variety of applications.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
By submitting this form, you consent to Cell & Gene Therapy Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.